DrugPatentWatch Database Preview
ZURAMPIC Drug Profile
Join the DrugPatentWatch Referral Program Get access to a free drug patent landscape report or a free one-month subscription
When do Zurampic patents expire, and when can generic versions of Zurampic launch?
Zurampic is a drug marketed by Ironwood Pharms Inc and is included in one NDA. There are nine patents protecting this drug.
This drug has one hundred and ninety-five patent family members in forty-one countries.
The generic ingredient in ZURAMPIC is lesinurad. One supplier is listed for this compound. Additional details are available on the lesinurad profile page.
US ANDA Litigation and Generic Entry Outlook for Zurampic
Zurampic will be eligible for patent challenges on December 22nd, 2019. This date may extended up to six months if a pediatric exclusivity extension is applied to the drug's patents.
By analyzing the patents and regulatory protections it appears that the earliest date
for generic entry will be February 29th, 2032. This may change due to patent challenges or generic licensing.
Summary for ZURAMPIC
International Patents: | 195 |
US Patents: | 9 |
Applicants: | 1 |
NDAs: | 1 |
Suppliers / Packagers: | 1 |
Bulk Api Vendors: | 63 |
Patent Applications: | 67 |
Drug Prices: | Drug price information for ZURAMPIC |
DailyMed Link: | ZURAMPIC at DailyMed |


Generic Entry Opportunity Date for ZURAMPIC
Generic Entry Date for ZURAMPIC*:
Constraining patent/regulatory exclusivity:
NDA:
Dosage:
TABLET;ORAL |
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
Pharmacology for ZURAMPIC
Drug Class | Urate Transporter 1 Inhibitor |
Mechanism of Action | Urate Transporter 1 Inhibitors Cytochrome P450 3A Inducers |
Synonyms for ZURAMPIC
(5-bromo-4-(1-cyclopropylnaphthalen-4-yl)-4H-1,2,4-triazol-3-ylthio)acetic acid |
{[5-bromo-4-(4-cyclopropylnaphthalen-1-yl)-4H-1,2,4-triazol-3-yl]sulfanyl}acetic acid |
09ERP08I3W |
2-((5-bromo-4-(4-cyclopropylnaphthalen-1-yl)-4H-1,2,4-triazol-3-yl)thio)acetic acid |
2-(5-bromo-4-(1-cyclopropylnaphthalen-4-yl)-4H-1,2,4-triazol-3-ylthio)acetic acid |
2-(5-Bromo-4-(4-cyclopropylnaphthalen-1-yl)-4H-1,2,4-triazol-3-ylthio)acetic acid |
2-[[5-Bromo-4-(4-cyclopropyl-1-naphthalenyl)-4H-1,2,4-triazol-3-yl]thio]-acetic acid |
2-[[5-bromo-4-(4-cyclopropylnaphthalen-1-yl)-1,2,4-triazol-3-yl]sulfanyl]acetic acid |
2-[[5-bromo-4-(4-cyclopropylnaphthalen-1-yl)-4H-1,2,4-triazol-3-yl]thio]acetic acid |
2-{[5-broMo-4-(4-cyclopropylnaphthalen-1-yl)-4H-1,2,4-triazol-3-yl]sulfanyl}acetic acid |
3777AH |
878672-00-5 |
AC-29310 |
Acetic acid, 2-((5-bromo-4-(4-cyclopropyl-1-naphthalenyl)-4H-1,2,4-triazol-3-yl)thio)- |
Acetic acid,[[5-bromo-4-(4-cyclopropyl-1-naphthalenyl)-4H-1,2,4-triazol-3-yl]thio]- |
ACN-050764 |
AK323774 |
AKOS027327368 |
BCP06435 |
BDBM37953 |
C17H14BrN3O2S |
CHEBI:90929 |
CHEMBL2105720 |
CS-1389 |
D09921 |
DB11560 |
EX-A1289 |
FGQFOYHRJSUHMR-UHFFFAOYSA-N |
GTPL7673 |
HY-15258 |
KB-78121 |
KS-00000LAE |
LESINURAD |
Lesinurad (RDEA-594) |
Lesinurad (RDEA594 pound(c) |
Lesinurad (RDEA594) |
Lesinurad (USAN/INN) |
Lesinurad [USAN:INN] |
Lesinurad, >=98% (HPLC) |
MolPort-039-138-666 |
RDEA 594 |
RDEA-594 |
RDEA594 |
s4640 |
SB16705 |
SC-94287 |
SCHEMBL842962 |
UNII-09ERP08I3W |
US10093631, Compound Lesinurad |
W-5949 |
ZINC84757007 |
Zurampic (TN) |
US Patents and Regulatory Information for ZURAMPIC
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Ironwood Pharms Inc | ZURAMPIC | lesinurad | TABLET;ORAL | 207988-001 | Dec 22, 2015 | DISCN | Yes | No | Start Trial | Start Trial | Y | Y | Start Trial | ||
Ironwood Pharms Inc | ZURAMPIC | lesinurad | TABLET;ORAL | 207988-001 | Dec 22, 2015 | DISCN | Yes | No | Start Trial | Start Trial | Y | Start Trial | |||
Ironwood Pharms Inc | ZURAMPIC | lesinurad | TABLET;ORAL | 207988-001 | Dec 22, 2015 | DISCN | Yes | No | Start Trial | Start Trial | Start Trial | ||||
Ironwood Pharms Inc | ZURAMPIC | lesinurad | TABLET;ORAL | 207988-001 | Dec 22, 2015 | DISCN | Yes | No | Start Trial | Start Trial | Y | Start Trial | |||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for ZURAMPIC
Country | Patent Number | Estimated Expiration |
---|---|---|
Norway | 2019008 | Start Trial |
Taiwan | 201302718 | Start Trial |
Ecuador | SP077322 | Start Trial |
Netherlands | 300825 | Start Trial |
>Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for ZURAMPIC
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
2135608 | 2016/033 | Ireland | Start Trial | PRODUCT NAME: (I)PRODUCT (I.E. ACTIVE INGREDIENT OR COMBINATION OF ACTIVE INGREDIENTS) FOR WHICH A CERTIFICATE IS REQUESTED:-LESINURAD, OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF.; REGISTRATION NO/DATE: EU/1/15/1080 20160218 |
2217577 | 300970 | Netherlands | Start Trial | PRODUCT NAME: DUZALLO - ALLOPURINOL/LESINURAD OF EEN FARMACEUTISCH AANVAARDBAAR ZOUT OF ZOUTEN DAARVAN; REGISTRATION NO/DATE: EU/1/18/1300 20180827 |
2217577 | 2019C/502 | Belgium | Start Trial | PRODUCT NAME: DUZALLO - ALLOPURINOL / LESINURAD OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE OU UN DE SES SELS; AUTHORISATION NUMBER AND DATE: EU/1/18/1300 20180827 |
2217577 | 2016016 | Norway | Start Trial | PRODUCT NAME: LESINURAD, ELLER ET; REG. NO/DATE: EU/1/15/1080 20160303 |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |